While approximately 95.7 percent of Nigerian breast cancer patients express readiness for genetic testing, the vast majority have a mean correct response rate of only 20.5 percent regarding recognized risk factors. The epidemiological landscape of Nigeria has undergone a profound transformation as
Legislative progress in 25 states has mandated biomarker testing coverage, yet many patients still face prohibitive cost-sharing requirements and frequent insurance denials for innovative modalities. The promise of precision medicine—the tailoring of medical treatment to the individual
Recent findings demonstrate that systemic methotrexate treatment exerts selective pressure on the DAMA genome, leading to significant increases in Myc and Kras mutation frequencies. This discovery marks a pivotal moment in 2026 for the oncology community, which has long struggled to find
Cancer reported in nine Zolgensma recipients is drawing fresh attention to a concern that gene therapy has faced for years. The FDA is investigating the cases, but says Zolgensma’s benefits still outweigh the possible risks when used as approved. For families and companies developing similar
The precision required to modify the synthetic base Z into Z* highlights the immense technical challenges of integrating artificial molecules into natural systems. For billions of years, the operating system of biological life has relied on a rigid four-letter script: Adenine, Thymine, Guanine, and
The tendency of clustering algorithms to fluctuate between different partitions creates a reproducibility crisis that necessitates a standardized, unsupervised solution. In the complex world of single-cell transcriptomics, the ability to accurately categorize individual cells into distinct
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59